Other OTC - Delayed Quote USD

Invitae Corporation (NVTAQ)

0.0005 -0.0085 (-94.44%)
At close: April 26 at 3:44 PM EDT
Key Events
Loading Chart for NVTAQ
DELL
  • Previous Close 0.0090
  • Open 0.0004
  • Bid --
  • Ask --
  • Day's Range 0.0004 - 0.0065
  • 52 Week Range 0.0001 - 1.6700
  • Volume 271,721
  • Avg. Volume 8,734,670
  • Market Cap (intraday) 143,246
  • Beta (5Y Monthly) 1.28
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date May 7, 2024 - May 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 0.30

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. On February 13, 2024, Invitae Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey.

www.invitae.com

1,700

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NVTAQ

Performance Overview: NVTAQ

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NVTAQ
99.92%
S&P 500
6.92%

1-Year Return

NVTAQ
99.96%
S&P 500
25.26%

3-Year Return

NVTAQ
100.00%
S&P 500
22.00%

5-Year Return

NVTAQ
100.00%
S&P 500
74.29%

Compare To: NVTAQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NVTAQ

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    143.25k

  • Enterprise Value

    1.25B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.00

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.60

  • Enterprise Value/EBITDA

    -0.98

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -299.14%

  • Return on Assets (ttm)

    -23.70%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    481.58M

  • Net Income Avi to Common (ttm)

    -1.44B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    254.57M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -34.7M

Research Analysis: NVTAQ

Analyst Price Targets

0.30
0.30 Average
0.0005 Current
0.30 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: NVTAQ

Fair Value

0.0005 Current
 

Dividend Score

0 Low
NVTAQ
Sector Avg.
100 High
 

Hiring Score

0 Low
NVTAQ
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
NVTAQ
Sector Avg.
100 High
 

People Also Watch